Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial-Reference-Cited by-同舟云学术

Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial

Published:2024-04 Issue:4 Volume:25 Page:463-473
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Kater Arnon P,Arslan Önder,Demirkan Fatih,Herishanu Yair,Ferhanoglu Burhan,Diaz Marcos Gonzalez,Leber Brian,Montillo Marco,Panayiotidis Panayiotis,Rossi Davide,Skarbnik Alan,Tempescul Adrian,Turgut Mehmet,Mellink Clemens H,van der Kevie-Kersemaekers Anne-Marie F,Lanham Stuart,Sale Ben,Del Rio Luis,Popovic Relja,Chyla Brenda J,Busman Todd,Komlosi Viktor,Wang Xifeng,Sail Kavita,Pena German E,Vizkelety Tamas,Forconi Francesco

Publisher

Elsevier BV

Reference22 articles.

1. Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib/II PCYC-1102 study;Byrd;Clin Cancer Res,2020

2. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma;Fraser;Leukemia,2019

3. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial;Jones;Lancet Oncol,2018

4. Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia;Davids;Clin Cancer Res,2018

5. The evolving landscape of chronic lymphocytic leukemia on diagnosis, prognosis and treatment;Pérez-Carretero;Diagnostics (Basel),2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia;Annals of Oncology;2024-09

2. Immunophenotyping of Peripheral Blood Cells in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib;Cells;2024-08-30

3. Integrative Analysis of Multi-Omics Data to Identify Deregulated Molecular Pathways and Druggable Targets in Chronic Lymphocytic Leukemia;Journal of Personalized Medicine;2024-08-06

4. Chronic Lymphocytic Leukemia: Prognostic Factors in the Era of Novel Drugs;Cancers;2024-07-31

5. Venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia;The Lancet Oncology;2024-04